Skip to content

Current Affairs

The viability of fetuses and the abortion debate

A paper has been published online in the British medical journal today
suggesting that survival of extremely premature infants (less than 24
weeks gestation) has not improved in the last decade. This comes less
than a week before a debate in the House of Commons on the Human
Fertilisation and Embryo Authority bill. It has been claimed that this
paper “completely blows out of the water” the arguments of
anti-abortion MPs who hope next week to push for a reduction in the
cut-off for legal abortion (currently 24 weeks).

Read More »The viability of fetuses and the abortion debate

The Apeman and the Scotsman: the slippery slope to humanzees

In the Scotsman this week there is an interview with a scientist who
has claimed that a loophole in the draft UK Human Fertilisation and
Embryology Bill is likely to lead to the creation of hybrid human-apes
or “humanzees”.

In essence this argument is a slippery slope objection to the proposed
changes in the powers of the UK regulatory authority for embryo and
fertilisation research.

Read More »The Apeman and the Scotsman: the slippery slope to humanzees

Football screens and genes: Should genetic discrimination in sport be banned?

In the Guardian this weekend, it is reported that at least one UK football club has been contemplating using genetic tests to screen potential recruits,in the hope of identifying future star players. This comes only one day after legislation was passed in the US Senate prohibiting insurance companies and employers from using genetic information in hiring or insurance decisions.

Read More »Football screens and genes: Should genetic discrimination in sport be banned?

Academic Integrity and Vioxx

Drug company Merck and its product Vioxx are in the news again. An article in the Journal of the American Medical Association (JAMA) has examined the documents from the legal proceedings against Merck in connection with the withdrawal of Vioxx from the market in 2004. From their analysis, a significant number of journal articles – mostly review articles rather than articles reporting clinical trials – were written in-house and senior academics were brought in late to be lead named author. At least one of these academics has disputed the accusations made in the JAMA article.

Read More »Academic Integrity and Vioxx

Expert advice

Last Friday, on BBC Radio 4’s Any Questions?, one of the questioners picked up a theme that had appeared many times in the media during the week.  ‘What is the point’, he asked, ‘of asking for advice from an expert independent panel of advisers and then disregarding it?’. 

He was referring to leaked information that the government’s  Advisory Commission on the Misuse of Drugs was going to recommend that cannabis should retain its current status as a class C drug, but that the Prime Minister was nevertheless ‘minded’ to restore its former B classification.  Class B drugs are regarded as more serious than those of class C, carrying a five year maximum prison sentence for possession, as opposed to the current two years. 

Read More »Expert advice

Helping human-animals to die

A French woman, Chantal Sebire with a disfiguring and painful terminal
illness recently failed in her appeal for medical assistance to help
her to die. Before her death Chantal Sebire was quoted as saying “We
wouldn’t let an animal go through what I have had to endure”(1).
Euthanasia for animals is commonplace, and is widely accepted as a
morally acceptable response to animals whose suffering is unable to be
relieved. But, with the exception of a few places such as the
Netherlands, Belgium and the US state of Oregon, euthanasia for humans
is legally prohibited.
But is it speciesist to make a distinction between animal and human
euthanasia? In the case of terminally ill humans who request medical
assistance in dying we may have more reasons to permit euthanasia than
in the case of animals. If the arguments against euthanasia are so
forceful that it should not be permitted even in tragic cases like that
of Chantal Sebire should animal euthanasia be prohibited?

Read More »Helping human-animals to die

Catholic Conscience and Hybrid Embryos

The first hybrid embryo was created yesterday and the debate about it and the HFEA Bill continues. Recently, the most senior Catholic scientist Sir Leszek Borysiewicz has criticised the Church for its position. Sir Leszek is quoted in The Times as saying:

I was brought up as a Catholic at home, both my parents are Catholics and I have continued to be a member of the Church … I go to church but I have had considerable issues with some of the stances the Church has taken on a variety of health-related issues. My conscience tells me very firmly that I should support the Bill as it stands.

Read More »Catholic Conscience and Hybrid Embryos

Is it Wrong to Deliberately Select Embryos which will have Disabiltites?

A current bill before Parliament would revise the current regulation of IVF. One clause has caused great debate, especially amongst people with disabilities. It states:

(9) Persons or embryos that are known to have a gene, chromosome or mitochondrion abnormality involving a significant risk that a person with the abnormality will have or develop—

(a) a serious physical or mental disability,
(b) a serious illness, or
(c) any other serious medical condition, must not be preferred to those that are not known to have such an abnormality.

Some people with disabilities like deafness or dwarfism wish to use IVF to select embryos with the same disabilities. For reports of such cases, see Sanghavi, D. M. ‘Wanting Babies Like Themselves, Some Parents Choose Genetic Defects’, The New York Times, (December 5, 2006).

According to a recent survey, deliberate selection of children with conditions such as deafness or dwarfism is not uncommon: 5% of 190 of PGD clinics surveyed in the US have allowed parents to select embryos with conditions commonly taken to be disabilities (See Baruch, S. Kaufman, D. and Hudson, K. L. ‘Genetic testing of embryos: practices and perspectives of U.S. IVF clinics’ Fertility and Sterility (2006).)

Read More »Is it Wrong to Deliberately Select Embryos which will have Disabiltites?

‘Reasonable steps’ to prevent gambling

The BBC
reports today
that a compulsive gambler has failed in a High Court bid to make
the bookmaker William Hill repay £2 million of his gambling losses. The gambler, Graham Calvert, claimed that the
bookmaker failed in its ‘duty of care’ by allowing him to continue to place
bets after he had asked the company to close his account. The judge recognised that William Hill failed
to take ‘reasonable steps’ to prevent Calvert from gambling, but said that it
was probable that Calvert would have continued to gamble even had such steps
been taken, meaning that William Hill is not responsible for his losses.

Does a
bookmaker have a duty of care towards its customers? The judge in the case thought not, so let us
pose a far more modest question: ought a bookmaker to take ‘reasonable steps’
to prevent its customers from gambling in certain cases? Answering ‘yes’ to the latter question raises
a number of puzzling questions. For
example, what counts as a reasonable step, and under what circumstances ought
such a step to be taken? Consider the
reasons we might believe that pathological gambling is bad: I suggest that
three important reasons are (1) that it is irrational, in that the gambling
behaviour of pathological gamblers is highly unlikely to help realise their goal
of winning money and is highly likely to frustrate this goal; (2) that
pathological gamblers gamble often, and gamble more money than they can afford
to lose; and (3) because of (1) and (2), pathological gamblers are likely to
suffer large financial losses, which can disrupt other aspects of their lives,
such as their personal relationships, health, and career. 

Read More »‘Reasonable steps’ to prevent gambling

The Transparency of Clinical Trials

An article in the current issue of Science examines the extent to which new policies regarding the governance of clinical trials promote transparency. It goes on to suggest further issues that remain unaddressed and require attention. The authors suggest that recent policy changes have improved the extent of public access to clinical trial data. In particular, they suggest that Section 801 of the FDA Amendments Act “should go a long way in ensuring that all patients and all data are publicly accounted for.” However, with the Editor-in-Chief of the New England Journal of Medicine, they do worry that some patients “are left on the cutting room floor to make a drug look better than it really is.”

Read More »The Transparency of Clinical Trials